Asclepes Research Centres — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$9,525	1
2022	Research	$67,754	7
2021	Research	$20,000	3
2020	Research	$11,716	2
2019	Research	$125,833	2

Breakdown

Who paid Research payments · program years 2019–2023

H. Lundbeck A S $165,457 11 payments
Teva Pharmaceuticals USA, Inc. $63,499 2 payments
Jazz Pharmaceuticals Inc. $5,871 2 payments

Studies the money was for Research payments · program years 2019–2023

Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD $98,407 1 payment
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $63,499 2 payments
Vortioxetine to Prevent Return of Symptoms in Children With Depression $27,909 7 payments
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD $27,426 1 payment
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $11,716 2 payments
Emerge 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca $5,871 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.